Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Open accessAbstract
Background Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors improve glycaemic control and reduce bodyweight in patients with type 2 diabetes through different mechanisms. We assessed the safety and efficacy of the addition of the once-weekly GLP-1 receptor agonist dulaglutide to the ongoing treatment regimen in patients whose diabetes is inadequately controlled with SGLT2 inhibitors, with or without metformin.Methods AWARD-10 was a phase 3b, double-blind, parallel-arm, placebo-controlled, 24-week study done at 40 clinical sites in Austria, Czech Republic, Germany, Hungary, Israel, Mexico, Spain, and the USA. Eligible adult patients (≥18 years) with inadequately controlled type 2 diabetes (HbA 1c concentration ≥7·0% [53 mmol/mol] and ≤9·5% [80 mmol/mol]), a BMI of 45 kg/m 2 or less, and taking stable doses (>3 months) of an SGLT2 inhibitor (with or without metformin) were randomly assigned (1:1:1) via an interactive web-response system to subcutaneous injections of either dulaglutide 1·5 mg, dulaglutide 0·75 mg, or placebo once per week for 24 weeks. Patients and investigators were masked to dulaglutide and placebo assignment, and those assessing outcomes were masked to study drug assignment. The primary objective was to test for the superiority of dulaglutide (1·5 mg or 0·75 mg) versus placebo for change in HbA 1c concentration from baseline at 24 weeks. All analyses were done in the intention-to-treat population, defined as all randomly assigned patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT02597049.Findings Between Dec 7, 2015, and Feb 3, 2017, 424 patients were randomly assigned to dulaglutide 1·5 mg (n=142), dulaglutide 0·75 mg (n=142), and placebo (n=140). One patient in the dulaglutide 0·75 mg group was excluded from the analysis because they did not receive any dose of the study drug. The reduction in HbA 1c concentration at 24 weeks was larger in patients receiving dulaglutide (least squares mean [LSM] for dulaglutide 1·5 mg -1·34% [SE 0·06] or -14·7 mmol/mol [0·6]; dulaglutide 0·75 mg -1·21% [0·06] or -13·2 mmol/mol [0·6]) than in patients receiving placebo (-0·54% [0·06] or -5·9 mmol/mol [0·6]; p<0·0001 for both groups vs placebo). The LSM differences were -0·79% (95% CI -0·97 to -0·61) or -8·6 mmol/mol (-10·6 to -6·7) for dulaglutide 1·5 mg and -0·66% (-0·84 to -0·49) or -7·2 mmol/mol (-9·2 to -5·4) for dulaglutide 0·75 mg (p<0·0001 for both). Serious adverse events were reported for five (4%) patients in the dulaglutide 1·5 mg group, three (2%) patients in the dulaglutide 0·75 mg group, and five (4%) patients in the placebo group. Treatment-emergent adverse events were more common in patients treated with dulaglutide than in patients who received placebo, mainly because of an increased incidence of gastrointestinal adverse events. Nausea (21 [15%] patients in the dulaglutide 1·5 mg group vs seven [5%] in the dulaglutide 0·75 mg group vs five [4%] in the placebo group), diarrhoea (eight [6%] vs 14 [10%] vs four [3%]), and vomiting (five [4%] vs four [3%] vs one [1%]) were more common with dulaglutide than with placebo. One episode of severe hypoglycaemia was reported in the dulaglutide 0·75 mg group. Two (1%) patients receiving dulaglutide 1·5 mg died, but these deaths were not considered to be related to study drug; no deaths occurred in the other groups.Interpretation Dulaglutide as add-on treatment to SGLT2 inhibitors (with or without metformin) resulted in significant and clinically relevant improvements in glycaemic control, with acceptable tolerability that is consistent with the established safety profile of dulaglutide.Funding Eli Lilly and Company.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · see citing works
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207 · see citing works
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · see citing works
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · see citing works
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · see citing works
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Nielsen, O. V., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615 · see citing works
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486 · see citing works
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30267-4 · Cited by 399 · see citing works
Self-citationWysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396 · see citing works
Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014) · Diabetes Care · doi:10.2337/dc13-2759 · Cited by 341 · see citing works
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284 · see citing works
Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268 · see citing works
Blonde, L., JENDLE, J. H., Gross, J. L., Woo, V. C., Jiang, H. H., Fahrbach, J. L., & Miličević, Z. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60936-9 · Cited by 228 · see citing works
Self-citationGerstein, H., Colhoun, H., Dagenais, G., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M., Rydén, L., Xavier, D., et al. (2018) · Diabetes, obesity and metabolism · doi:10.1111/dom.13028 · Cited by 179 · see citing works
Bretz, F., Posch, M., Glimm, E., Klinglmueller, F., Maurer, W., & Rohmeyer, K. (2011) · Biometrical Journal · doi:10.1002/bimj.201000239 · Cited by 172 · see citing works
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158 · see citing works
Weinstock, R. S., Guerci, B., Umpierrez, G. E., Nauck, M. A., Skrivanek, Z., & Miličević, Z. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12479 · Cited by 151 · see citing works
Pozzilli, P., Norwood, P., Jódar, E., Davies, M. J., Ivanyi, T., Jiang, H., Woodward, D. B., & Milicevic, Z. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12937 · Cited by 137 · see citing works
Self-citationAddressing Missing Data in Clinical Trials
Fleming, T. R. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00010 · Cited by 120 · see citing works
Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Mathieu, C., Woo, V., Wysham, C., Capuano, G., Desai, M., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12589 · Cited by 91 · see citing works
Hansen, L., Iqbal, N., Ekholm, E., Cook, W., & Hirshberg, B. (2014) · Endocrine Practice · doi:10.4158/ep14489.or · Cited by 63 · see citing works
SGLT-2 Inhibitor Therapy Added to GLP-1 Agonist Therapy in the Management of T2DM
Saroka, R. M., Kane, M. P., Busch, R. S., Watsky, J., & Hamilton, R. A. (2015) · Endocrine Practice · doi:10.4158/ep15877.or · Cited by 43 · see citing works
Yu, M., Mody, R., Landó, L. F., Shui, A., Kallenbach, L., Slipski, L., & de Oliveira, C. P. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.001 · Cited by 15 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- 2017, Standards of medical care in diabetes—2017. Summary of revisions, Diabetes Care, 40, S4
Cited by
Sorted by citations
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · see citing works
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598 · see citing works
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455 · see citing works
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192 · see citing works
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596 · see citing works
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581 · see citing works
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · see citing works
“The respective affinities of GIP(1-42) and GLP-1(736) as determined by radioligand binding were 200 pM and 700 pM, consistent with the literature (51, 52).”
BackgroundMethodResultInfluentialBuse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetologia · doi:10.1007/s00125-019-05039-w · Cited by 487 · see citing works
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466 · see citing works
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376 · see citing works
Self-citationNeuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067584 · Cited by 358 · see citing works
Emerging role of SGLT-2 inhibitors for the treatment of obesity
Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342 · see citing works
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 268 · see citing works
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.094 · Cited by 236 · see citing works
Brown, E. E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222 · see citing works
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192 · see citing works
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Talha, K. M., Anker, S. D., & Butler, J. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0030 · Cited by 196 · see citing works
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Sorice, G. P., Mezza, T., Pontecorvi, A., & Giaccari, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0828-y · Cited by 180 · see citing works
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153 · see citing works
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 161 · see citing works
Scheen, A. J. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.008 · Cited by 146 · see citing works
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
Trujillo, J. M. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13225 · Cited by 131 · see citing works
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.003 · Cited by 132 · see citing works
Gourdy, P., Darmon, P., Diévart, F., Halimi, J., & Guerci, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01798-4 · Cited by 128 · see citing works
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 129 · see citing works
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes · doi:10.2337/dbi20-0040 · Cited by 123 · see citing works
New pharmacological strategies for protecting kidney function in type 2 diabetes
Muskiet, M. H. A., Wheeler, D. C., & Heerspink, H. J. L. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30263-8 · Cited by 107 · see citing works
Xian, Y., Weng, J., & Xu, F. L. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001263 · Cited by 106 · see citing works
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105 · see citing works
Mantsiou, C., Karagiannis, T., Kakotrichi, P., Malandris, K., Avgerinos, I., Liakos, A., Tsapas, A., & Bekiari, E. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14108 · Cited by 98 · see citing works
Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97 · see citing works
Jabbour, S. A., Frías, J. P., Hardy, E., Ahmed, A., Wang, H., Öhman, P., & Guja, C. (2018) · Diabetes Care · doi:10.2337/dc18-0680 · Cited by 97 · see citing works
Self-citationLi, C., Jie, L., Jiang, M., & Wang, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838277 · Cited by 97 · see citing works
Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., Gustavson, S., Sjöström, C. D., Ruggles, J. A., Hernandez, A. F., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0942-x · Cited by 94 · see citing works
Mody, R., Huang, Q., Yu, M., Zhao, R., Patel, H., Grabner, M., & Landó, L. F. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13603 · Cited by 93 · see citing works
Dave, C. V., Kim, S. C., Goldfine, A. B., Glynn, R. J., Tong, A., & Patorno, E. (2020) · Circulation · doi:10.1161/circulationaha.120.047965 · Cited by 92 · see citing works
Castellana, M., Cignarelli, A., Brescia, F., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-55524-w · Cited by 87 · see citing works
Garg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82 · see citing works
Gan, S., Dawed, A. Y., Donnelly, L. A., Nair, A. T. N., Palmer, C. N. A., Mohan, V., & Pearson, E. R. (2020) · Diabetes Care · doi:10.2337/dc19-2419 · Cited by 82 · see citing works
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lópes, R. D., Al‐Khalidi, H. R., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 79 · see citing works
Romera, I., Cebrián-Cuenca, A., Álvarez-Guisasola, F., Gomez-Peralta, F., & Reviriego, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0535-9 · Cited by 77 · see citing works
Frías, J. P. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1830759 · Cited by 73 · see citing works
Self-citationMosenzon, O., Prato, S. D., Schechter, M., Leiter, L. A., Ceriello, A., DeFronzo, R. A., & Raz, I. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01281-y · Cited by 72 · see citing works
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
Neves, J. S., Borges‐Canha, M., Vasques‐Nóvoa, F., Green, J. B., Leiter, L. A., Granger, C. B., Carvalho, D. M., Leite-Moreira, A. F., Hernandez, A. F., Prato, S. D., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.048 · Cited by 72 · see citing works
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71 · see citing works
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 70 · see citing works
Jabbour, S. A., Frías, J. P., Ahmed, A., Hardy, E., Choi, J., Sjöström, C. D., & Guja, C. (2020) · Diabetes Care · doi:10.2337/dc19-1350 · Cited by 69 · see citing works
Self-citationPhilis‐Tsimikas, A., Billings, L. K., Busch, R. S., Morales, C., Sahay, R. K., Halladin, N., Eggert, S., Begtrup, K., & Harris, S. B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13666 · Cited by 69 · see citing works
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Eguchi, Y., Ono, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061907 · Cited by 67 · see citing works
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66 · see citing works
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
Brown, E. E., Wilding, J. P. H., Alam, U., Barber, T. M., Karalliedde, J. J., & Cuthbertson, D. J. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1841281 · Cited by 65 · see citing works
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 67 · see citing works
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65 · see citing works
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 87 · see citing works
Gonçalves, E., & Bell, D. S. H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0420-6 · Cited by 61 · see citing works
Guo, M., Gu, J., Teng, F., Chen, J., Ma, X., Chen, Q., Pu, Y., Jiang, Z., Long, Y., & Xu, Y. (2020) · Endocrine · doi:10.1007/s12020-019-02175-6 · Cited by 60 · see citing works
Janež, A., & Fioretto, P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01104-z · Cited by 59 · see citing works
Tan, Y., Liu, S., & Tang, Q. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02468-5 · Cited by 57 · see citing works
van Ruiten, C. C., Smits, M. M., Kok, M. D., Serné, E. H., van Raalte, D. H., Kramer, M. H. H., Nieuwdorp, M., & IJzerman, R. G. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01492-x · Cited by 56 · see citing works
Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 63 · see citing works
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90 · see citing works
Blonde, L., Belousova, L., Fainberg, U., Garcia‐Hernandez, P. A., Jain, S. M., Kaltoft, M. S., Mosenzon, O., Nafach, J., Palle, M. S., & Rea, R. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13978 · Cited by 54 · see citing works
van Ruiten, C. C., der Beek, A. B. V. D. A., IJzerman, R. G., Nieuwdorp, M., Hoogenberg, K., van Raalte, D. H., & Heerspink, H. J. L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14410 · Cited by 54 · see citing works
Dulaglutide: A Review in Type 2 Diabetes
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01260-9 · Cited by 51 · see citing works
Cahn, A., Wiviott, S. D., Mosenzon, O., Murphy, S. A., Goodrich, E. L., Yanuv, I., Rozenberg, A., Wilding, J. P. H., Leiter, L. A., Bhatt, D. L., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14179 · Cited by 51 · see citing works
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 49 · see citing works
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 49 · see citing works
Anderson, J. E. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0031 · Cited by 49 · see citing works
Scheen, A. J. (2024) · Drugs · doi:10.1007/s40265-024-02090-9 · Cited by 47 · see citing works
Zhang, Y., Chen, G., Wang, W., Yang, D., Zhu, D., & Jing, Y. (2024) · Bone · doi:10.1016/j.bone.2024.117338 · Cited by 50 · see citing works
Matza, L. S., Boye, K. S., Stewart, K. D., Coyne, K. S., Wullenweber, P. K., Cutts, K. N., Jordan, J. B., Wang, Q., Yu, M. B., Currie, B. M., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13902 · Cited by 46 · see citing works
Self-citationHu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 46 · see citing works
Nuhoho, S., Gupta, J., Hansen, B. B., Fletcher-Louis, M., Dang‐Tan, T., & Paine, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00706-y · Cited by 41 · see citing works
Janež, A., Muzurović, E. M., Stoian, A. P., Haluzı́k, M., Guja, C., Czupryniak, L., Duvnjak, L. S., Lalic, N. M., Tankova, T. I., Bogdański, P., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.017 · Cited by 42 · see citing works
Hupa‐Breier, K. L., Dywicki, J., Hartleben, B., Wellhöner, F., Heidrich, B., Taubert, R., Mederacke, Y., Lieber, M., Iordanidis, K., Manns, M. P., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9040353 · Cited by 40 · see citing works
Xia, L., Shen, T., Dong, W., Feng, S., Wang, J., Wang, Q., Niu, S., & Fang, Y. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108904 · Cited by 41 · see citing works
Candler, T. P., McGregor, D., Narayan, K., Moudiotis, C., & Burren, C. P. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0389 · Cited by 39 · see citing works
Real‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study
Tofé, S., Argüelles, I., Mena, E., Serra, G., Codina, M., Urgelés, J. R., García, H., & Pereg, V. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.51 · Cited by 37 · see citing works
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36 · see citing works
Saponaro, C., Gmyr, V., Thévenet, J., Moerman, E., Delalleau, N., Pasquetti, G., Coddeville, A., Quenon, A., Daoudi, M., Hübert, T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.009 · Cited by 36 · see citing works
Díaz-Trastoy, O., Villar‐Taibo, R., Sifontes-Dubón, M., Mozo-Peñalver, H., Bernabéu, I., Cabezas-Agrícola, J. M., Muñoz-Leira, V., Peinó-García, R., Martís-Sueiro, A., López, J. M. G., et al. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.12.012 · Cited by 36 · see citing works
Arnott, C. G., Neuen, B. L., Heerspink, H. J. L., Figtree, G. A., Kosiborod, M., Lam, C. S. P., Cannon, C. P., Rosenthal, N. R., Shaw, W. C., Mahaffey, K. W., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.06.011 · Cited by 36 · see citing works
Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 43 · see citing works
Mousavi, A., Shojaei, S., Soleimani, H., Semirani-Nezhad, D., Ebrahimi, P., Zafari, A., Ebrahimi, R., Roozbehi, K., Harrison, A., Syed, M., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01635-6 · Cited by 33 · see citing works
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
Gajjar, A., Raju, A. K. V., Gajjar, A. J., Menon, M., Shah, S. A. Y., Dani, S. S., & Weinberg, A. M. (2025) · Biomedicines · doi:10.3390/biomedicines13081924 · Cited by 38 · see citing works
Singh, A. K., & Singh, R. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i6.329 · Cited by 32 · see citing works
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
Lunati, M. E., Cimino, V., Bernasconi, D. P., Gandolfi, A., Morpurgo, P. S., Tinari, C., Lazzaroni, E., Baruffaldi, L., Muratori, M., Montefusco, L. B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107040 · Cited by 31 · see citing works
A Comprehensive Analysis of Diabetic Complications and Advances in Management Strategies
IWASAKI, H. O., Yagyu, H., & Shimano, H. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65551 · Cited by 36 · see citing works
Nørgaard, C. H., Starkopf, L., Gerds, T. A., Vestergaard, P., Bonde, A. N., Fosbøl, E. L., Køber, L., Wong, N. D., Torp-Pedersen, C. T., & Lee, C. J.-Y. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab053 · Cited by 31 · see citing works
Block, C. E. M. D., Dirinck, E. L., Verhaegen, A. A., & Gaal, L. F. V. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 31 · see citing works
Alkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 32 · see citing works
The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs
Rodbard, H. W. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0103 · Cited by 30 · see citing works
Zhou, Y., Geng, Z., Wang, X., Huang, Y., Shen, L., & Wang, Y. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3223 · Cited by 30 · see citing works
Obesidad y diabetes mellitus tipo 2: también unidas en opciones terapéuticas
Rubio-Almanza, M., Cámara-Gómez, R., & Merino-Torres, J. F. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.003 · Cited by 30 · see citing works
Vernstrøm, L., Gullaksen, S., Sørensen, S. S., Funck, K. L., Laugesen, E., & Poulsen, P. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15464 · Cited by 30 · see citing works
Obesity and type 2 diabetes: Also linked in therapeutic options
Rubio-Almanza, M., Cámara-Gómez, R., & Merino-Torres, J. F. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.11.006 · Cited by 29 · see citing works
van Ruiten, C. C., Veltman, D. J., Schrantee, A., van Bloemendaal, L., Barkhof, F., Kramer, M. H. H., Nieuwdorp, M., & IJzerman, R. G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac043 · Cited by 33 · see citing works
Bertoluci, M. C., Salles, J. E. N., Silva‐Nunes, J., Pedrosa, H. C., Moreira, R. O., Duarte, R., Carvalho, D. M., Trujilho, F. R., Raposo, J. F. C. D. S., Parente, E. B., et al. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00551-1 · Cited by 28 · see citing works
Carretero‐Gómez, J., Arévalo‐Lorido, J. C., Gómez‐Huelgas, R., de Lucas, M. D. G., Polo, L. M., Aguilar, J. M. V., Ripoll, J. M. S., & Ena, J. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.09.001 · Cited by 28 · see citing works
- Authors
- Ludvik, B., Frías, J. P., Tinahones, F. J., Wainstein, J., Jiang, H., Robertson, K. E., García-Pérez, L.-E., Woodward, D. B., & Milicevic, Z.
- Affiliations
- Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
- National Research Institute (US)
- Instituto de Salud Carlos III (ES)
- Tel Aviv University (IL)
- Eli Lilly (United States) (US)
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 6
- Issue
- 5
- Pages
- 370-381
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2788154323
- Cited by
- 266
- References
- 27
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 22 · 2023: 21 · 2022: 30 · 2021: 27 · 2020: 51 · 2019: 37 · 2018: 26
- FWCI
- 28.03
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- ResearchOnline - JCU (James Cook University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- SGLT2 inhibitors, type 2 diabetes, inadequate glycaemic control, adjunctive therapy, GLP-1 receptor agonists, HbA1c, metformin, body weight, adverse events, obesity, drug safety and efficacy, dose comparison, subcutaneous injection, HbA1c reduction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Recombinant Fusion Proteins, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
